Page 1360 - Williams Hematology ( PDFDrive )

1334 Part X: Malignant Myeloid Diseases Chapter 86: Primary Myelofibrosis 1335

200. Bartlett RP, Greipp PR, Tefferi A, et al: Extramedullary hematopoiesis manifesting as a 236. Mohite U, Pathare A, Al Kindi S, et al: Autoimmune haemolytic anemia as the present-
symptomatic pleural effusion. Mayo Clin Proc 70:1165, 1995. ing manifestation of agnogenic myeloid metaplasia. Haematologica 32:495, 2002.
201. Oren I, Goldman A, Haddad N, et al: Ascites and pleural effusion secondary to 237. Kornblihtt LI, Vassalllu PS, Heller PG, et al: Primary myelofibrosis in a patient who
extramedullary hematopoiesis. Am J Med Sci 318:286, 1999. developed primary biliary cirrhosis, autoimmune hemolytic anemia and fibrillary glo-
202. Lioté F, Yeni P, Teillet-Thiebaud F, et al: Ascites revealing peritoneal and hepatic merulonephritis. Ann Hematol 87:1019, 2008.
extramedullary hematopoiesis with peliosis in agnogenic myeloid metaplasia. Am J 238. Schreiber ZA: Immune thrombocytopenia in postpolythemic myelofibrosis. Am J
Med 90:111, 1991. Hematol 54:146, 1997.
203. Vilaseca J, Arnau JM, Tallada N, et al: Agnogenic myeloid metaplasia presenting as 239. Seelen MA, de Meijer PH, Posthuma EF, Meinders AE: Myelofibrosis and thrombocy-
massive pericardial effusion due to extramedullary hematopoiesis. Acta Haematol topenic purpura. Ann Hematol 75:129, 1997.
73:239, 1985. 240. Wang JC, Wang A: Plasma soluble interleukin-2 receptor in patients with primary mye-
204. Haedersdal C, Hasselbalch H, Devantier A, et al: Pericardial haematopoiesis with tam- lofibrosis. Br J Haematol 86:380, 1994.
ponade in myelofibrosis. Scand J Haematol 34:270, 1985. 241. Leoni P, Rupoli S, Salvi A, et al: Antibodies against terminal galactosyl alpha(1–3)
205. Imam TH, Doll DC: Acute cardiac tamponade associated with pericardial extramedul- galactose epitopes in patients with idiopathic myelofibrosis. Br J Haematol 85:313,
lary hematopoieses in agnogenic myeloid metaplasia. Acta Haematol 98:42, 1997. 1993.
206. Nagler A, Brenner B, Argov S, et al: Postsplenectomy pericardial effusion in two 242. Bernhardt B, Valleta M: Lupus anticoagulant in myelofibrosis. Am J Med Sci 272:229,
patients with myeloid metaplasia. Arch Intern Med 146:600, 1986. 1976.
207. Pedio G, Krause M, Jansova I: Megakaryocytes in ascitic fluid in a case of agnogenic 243. Cappio FC, Vigliani R, Novarino A, et al: Idiopathic myelofibrosis: A possible role for
myeloid metaplasia [letter]. Acta Cytol 29:89, 1985. immune-complexes in the pathogenesis of bone marrow fibrosis. Br J Haematol 49:17,
208. Silverman JF: Extramedullary hematopoietic ascitic fluid cytology in myelofibrosis. Am 1981.
J Clin Pathol 84:125, 1985. 244. Akikusa B, Komatsu T, Kondo Y, et al: Amyloidosis complicating idiopathic myelofi-
209. Stephenson RW, Britt DA, Schumann GB: Primary cytodiagnosis of peritoneal brosis. Arch Pathol Lab Med 111:525, 1987.
extramedullary hematopoiesis. Diagn Cytopathol 2:241, 1986. 245. Hasselbalch H, Nielsen H, Berild D, et al: Circulating immune complexes in myelofi-
210. Hocking WG, Lazar GS, Lipsett JA, et al: Cutaneous extramedullary hematopoiesis fol- brosis. Scand J Haematol 34:177, 1985.
lowing splenectomy for idiopathic myelofibrosis. Am J Med 76:956, 1984. 246. Gordon BR, Coleman M, Kohen P, et al: Immunologic abnormalities in myelofibrosis
211. Partanen S, Ruutu T, Jubonen E, et al: Effect of splenectomy on circulating haematopoi- with activation of the complement system. Blood 58:904, 1981.
etic progenitors in myelofibrosis. Scand J Haematol 37:87, 1986. 247. Ferhanoğlu B, Erzin Y, Başlar Z, Tüzüner HA: Secondary amyloidosis in the course of
212. Hirose Y, Masaki Y, Shimoyama K, et al: Granulocytic sarcoma of megakaryoblastic idiopathic myelofibrosis. Leuk Res 21:897, 1997.
differentiation in the lymph nodes terminating as acute megakaryocytic leukemia in 248. Tefferi A, Kantarjian HM, Pardanani AD, et al: The clinical phenotype of myelofibrosis
a case of chronic idiopathic myelofibrosis persisting 16 years. Eur J Haematol 67:194, encompasses a chronic inflammatory state that is favorably altered by INCB018424, a
2001. selective inhibitor of JAK1/2. Blood 112:968, 2008.
213. Chan ACL, Kwong Y-L, Lam CCK: Granulocytic sarcoma megakaryoblastic differenti- 249. el Mouzan MI, Ahmad MA, al Fadel Saleh M, et al: Myelofibrosis and pancytopenia in
ation complicating chronic idiopathic myelofibrosis. Hum Pathol 27:417, 1996. systemic lupus erythematosus. Am J Med 81:935, 1986.
214. Oishi N, Swisher SN, Stormont JM, et al: Portal hypertension in myeloid metaplasia. 250. Matsouka CH, Lioouris J, Andrianokis A: Systemic lupus erythematosus and myelofi-
Arch Surg 81:80, 1960. brosis. Clin Rheumatol 8:402, 1989.
215. Rosenbaum DL, Murphy GW, Swisher SN: Hemodynamic studies of the portal circula- 251. Paquette RL, Meshkinpour A, Rosen PJ: Autoimmune myelofibrosis. A steroid-
tion in myeloid metaplasia. Am J Med 41:360, 1966. responsive cause of bone marrow fibrosis associated with systemic lupus erythemato-
216. Jacobs P, Maze S, Tayob F, et al: Myelofibrosis, splenomegaly, and portal hypertension. sus. Medicine (Baltimore) 73:145, 1994.
Acta Haematol 74:45, 1985. 252. Ramakrishna R, Kyle PW, Day PJ, Mansharan A: Evan’s syndrome, myelofibrosis and sys-
217. Dubois A, Dauzat M, Pignodel C, et al: Portal hypertension in lymphoproliferative and temic lupus erythematosus: Role of procollagens in myelofibrosis. Pathology 27:255, 1995.
myeloproliferative disorders: Hemodynamic and histological correlations. Hepatology 253. Kiss E, Gál I, Simkovics E, et al: Myelofibrosis in systemic lupus erythematosus. Leuk
17:246, 1993. Lymphoma 39:661, 2000.
218. Degott C, Carpon JP, Bettan L, et al: Myeloid metaplasia, perisinusoidal fibrosis, and 254. Aharon A, Levy Y, Bar-Dayan Y, et al: Successful treatment of early secondary myelofi-
nodular regenerative hyperplasia of the liver. Liver 5:276, 1985. brosis in SLE with IVIG. Lupus 6:408, 1997.
219. Bioulac-Sage P, Roux D, Quinton A, et al: Ultrastructure of sinusoids in patients with 255. von Knorring J, Selroos O, Wasastjerna C, Wegelius O: Myeloid metaplasia in dissemi-
agnogenic myeloid metaplasia. J Submicrosc Cytol 18:815, 1986. nated vascular disease. Acta Med Scand 195:137, 1974.
220. Roux D, Merlio JP, Quinton A, et al: Agnogenic myeloid metaplasia, portal hyperten- 256. Connelly TJ, Abruzzo JL, Schwab RH: Agnogenic myeloid metaplasia with polyarteri-
sion and sinusoidal abnormalities. Gastroenterology 92:1067, 1987. tis. J Rheumatol 9:954, 1982.
221. Tsao MS: Hepatic sinusoidal fibrosis in agnogenic myeloid metaplasia. Am J Clin Pathol 257. Arellano-Rodrigo E, Esteve J, Giné E, et al: Idiopathic myelofibrosis associated with
91:302, 1989. ulcerative colitis. Leuk Lymphoma 43:1481, 2002.
222. Pereira A, Bruguera M, Cervantes F, Rozman C: Liver involvement at diagnosis of pri- 258. Ben-Chetrit E, Gross DJ, Ikon E, et al: The association between auto-immunity and
mary myelofibrosis: A clinicopathological study of twenty-two cases. Eur J Haematol agnogenic myeloid metaplasia. Scand J Haematol 31:410, 1983.
40:355, 1988. 259. Hernández-Beluda JC, Jiménez M, Rosiñol L, Cervantes F: Idiopathic myelofibrosis
223. Valla D, Casadevall N, Huisse MG, et al: Etiology of portal vein thrombosis in adults. associated with primary biliary cirrhosis. Leuk Lymphoma 43:673, 2002.
Gastroenterology 94:1063, 1988. 260. Marie I, Levesque H, Cailleux N, et al: An uncommon association: Sjögren syndrome
224. Lee W-C, Lin H-C, Tsay S-H, et al: Esophageal variceal ligation for esophageal variceal and autoimmune myelofibrosis. Rheumatology 38:370, 1999.
hemorrhage in a patient with portal and primary pulmonary hypertension complicat- 261. Hasselbalch H, Jans H, Nielsen PL: A distinct subtype of idiopathic myelofibrosis with
ing myelofibrosis. Dig Dis Sci 46:915, 2001. bone marrow features mimicking hairy cell leukemia: Evidence of an autoimmune
225. Yusen RD, Kollef MH: Acute respiratory failure due to extramedullary hematopoiesis. pathogenesis. Am J Hematol 25:225, 1987.
Chest 108:1170, 1995. 262. Thiele J, Chen Y-S, Kvasnicka H-M, et al: Evolution of fibro-osteosclerotic bone mar-
226. Steensma DP, Hook CC, Stafford SL, Tefferi A: Low-dose, single fraction, whole-lung row lesions in primary (idiopathic) osteomyelofibrosis—A histomorphometric study
radiotherapy for pulmonary hypertension associated with myelofibrosis and myeloid on sequential trephine biopsies. Leuk Lymphoma 14:163, 1994.
metaplasia. Br J Haematol 118:813, 2002. 263. Thiele J, Hoeppner B, Zankovich R, Fischer R: Histomorphometry of bone marrow
227. Cortelezzi A, Gritti G, et al: Pulmonary arterial hypertension in primary myelofibrosis biopsies in primary osteomyelofibrosis-sclerosis (agnogenic myeloid metaplasia): Cor-
is common and associated with an altered angiogenic status. Leukemia 22:646, 2008. relation between clinical and morphological features. Virchows Arch 415:191, 1989.
228. Popat U, Frost A, Liu E, et al: New onset of myelofibrosis in association with pulmonary 264. Guermazi A, de Kerviler E, Cazals-Hatem D, et al: Imaging findings in myelofibrosis.
arterial hypertension. Ann Intern Med 143:466, 2005. Eur J Radiol 9:1366, 1999.
229. Boivin P, Bernard JF, Hakim J, Woroclans M: Anomalies immunitaires au cours de sple- 265. Thiele J, Kvasnicka HM, Fischer R: Histochemistry and morphometry on bone marrow
nomegalies myeloides myelosclerose. Acta Haematol 51:91, 1974. biopsies in chronic myeloproliferative disorders: Aids to diagnosis and classification.
230. Lang JM, Oberling F, Mayer S, et al: Autoimmunity in primary myelofibrosis. Biomedicine Ann Hematol 78:496, 1999.
25:39, 1976. 266. Poulsen LW, Melsen F, Bendix K: Histomorphometric study of haematologic disorders
231. Barge J, Slabodshy-Brousse N, Bernard JF: Histoimmunology of myelofibrosis: A study with respect to marrow fibrosis and osteosclerosis. Acta Pathol Microbiol Immunol
of 100 cases. Biomedicine 29:73, 1978. Scand 106:495, 1998.
232. Vellenga E, Mulder NH, The TH, Nieweg HO: A study of the cellular and humoral 267. Coindre JM, Reiffers J, Goussot JF, et al: Histomorphometric analysis of sclerotic bone
immune response in patients with myelofibrosis. Clin Lab Haematol 4:239, 1982. from idiopathic myeloid metaplasia. J Pathol 144:163, 1984.
233. Rondeau E, Solal-Celigny P, Dhermy D, et al: Immune disorders in agnogenic myeloid 268. Diamond T, Smith A, Schnier R, Manoharan A: Syndrome of myelofibrosis and osteo-
metaplasia: Relations to myelofibrosis. Br J Haematol 53:467, 1983. sclerosis: A series of case reports and review of the literature. Bone 3:498, 2002.
234. Gordon B: Immunological abnormalities in myelofibrosis. Prog Clin Biol Res 154:455, 269. Parfitt AM, Drezner MK, Glorieux FH, et al: Bone histomorphometry: Standardization
1984. of nomenclature, symbols, and units. J Bone Miner Res 2:595, 1987.
235. Khumbanonda M, Horowitz HI, Eyster ME: Coombs’ positive hemolytic anemia in 270. Cassi E, DePaoli A, Tosi A, et al: Pure osteolytic lesions in myelofibrosis: Report of
myelofibrosis with myeloid metaplasia. Am J Med Sci 258:89, 1969. 2 cases. Haematologica 70:178, 1985.

Kaushansky_chapter 86_p1319-1340.indd 1335 9/18/15 10:24 AM